Compare Cassava Sciences Inc (FLNA) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Humana Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Humana Inc trades at $379.66 (market cap $44.77B). The key difference: Humana Inc is far larger — about 937.6× Cassava Sciences Inc's market cap, and Humana Inc pays a 0.95% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HUM | |
|---|---|---|
Market Cap | $47.75M | $44.77B |
Sector | Health | Health |
52-Week High | $4.64 | $409.42 |
52-Week Low | $0.87 | $163.67 |
Enterprise Value | -$34.93M | $52.12B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Humana (HUM) trades at $385.47, up 0.12% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth remains robust, reaching $129.66B in 2025, though net income margins have compressed to 0.88%. Recent news highlights leadership changes and Medicaid contract wins, while analyst consensus leans Hold with a $409.93 price target.
Outlook is mixed: Medicare Advantage margin expansion plans and cost controls offer upside, but regulatory pressures and margin erosion pose risks. The stock presents a cautious opportunity for investors betting on operational turnaround, with technical support near $382.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
